Screener / SEC EDGAR /CIK 0000874015 /10-K filed Feb 26, 2026, compared with Feb 19, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Pharmaceuticals

Ionis Pharmaceuticals Inc IONS

For three decades, we have invented medicines that bring better futures to people with serious diseases. 10-K, Item 1

Employees
1,402
Headquarters
Carlsbad, CA
CEO
Brett P. Monia
Next results
around Jan 11, 2027
Compare with peers Embed

IONS among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 33.8%, above 84% of 154 peers (their median 10.4%) REVENUE GROWTH 33.8% · above 84% Operating margin: -58.8%, above 10% of 138 peers (their median 10.2%) OPERATING MARGIN -58.8% · above 10% Net margin: -56.9%, above 10% of 153 peers (their median 6.8%) NET MARGIN -56.9% · above 10% FCF margin: -64.2%, above 8% of 144 peers (their median 10.1%) FCF MARGIN -64.2% · above 8%
IONS Peer median Below the median

What changed

16 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 26, 2026 against Feb 19, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

10 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 9 checks found nothing to note

  • Critical audit matters changed
    New this year: Auditing the (“How We Addressed the Matter in Our Audit We obtained an understanding and evaluated the design and tested the operating effectiveness of controls over the accounting for accrued clinical development expenses. This included controls over management's assessment of the assumptions and accuracy of data”); Company’s accruals for clinical and contract research organization costs is (“How We Addressed the Matter in Our Audit We obtained an understanding and evaluated the design and tested the operating effectiveness of controls over the accounting for accrued clinical development expenses. This included controls over management's assessment of the assumptions and accuracy of data”). No longer listed: Auditing the Company’s accruals for clinical and contract research organization costs is especially complex as the information necessary to estimate. Same as last year: Estimated Liability for Clinical Development Costs
  • Cash from operations −$268.6M vs net income −$381.4M (FY ending Dec 31, 2025)
8 more checks with nothing to note
  • Inventory -19.7% ($12.5M to $10.0M) vs revenue +33.8% ($705.1M to $943.7M), -53.5 pts apart
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

16 paragraphs in Risk Factors that were not in the 10-K filed Feb 19, 2025. Quoted as filed.

All 16 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
    Further, we believe that future coverage, reimbursement and pricing will likely be subject to increased restrictions both in the U.S. and in international markets. In the U.S., recent health reform measures have resulted in reductions in Medicare and other healthcare funding, and there have been several recent U.S. Congressional…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
    For example, while we continue to activate sites in the U.S., Canada, U.K., Australia and Japan, we revised and resubmitted the study protocol for the REVEAL study of obudanersen to address changes requested by EU regulators and plan to initiate EU sites for this study in 2026. Importantly, we believe we are on track to complete…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
    In addition, our development and commercialization activities could be harmed or delayed by staffing shortages or a shutdown or other significant disruption of the U.S. government, including the FDA or the U.S. PTO.
  4. Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
    We use artificial intelligence in certain aspects of our business, and challenges with properly managing its use could adversely affect our business. We incorporate artificial intelligence, or AI, solutions into certain aspects of our business, and applications of AI may become important in our operations over time. Our competitors or…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$587.4M$787.6M$705.1M$943.7M
Net income−$269.7M−$366.3M−$453.9M−$381.4M
Operating cash flow−$274.4M−$307.5M−$500.9M−$268.6M
Free cash flow−$290.1M−$331.3M−$546.2M−$320.0M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$943.7M ▲ 33.8% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

5 filings in the last 30 days · SEC EDGAR

All filings

About the company

Ionis Pharmaceuticals Inc, Carlsbad, CA · from the 10-K filed Feb 26, 2026

For three decades, we have invented medicines that bring better futures to people with serious diseases. As a pioneer in RNA-targeted medicines with a deep understanding of disease biology and an industry-leading drug discovery technology, we are driven to deliver innovative, life-changing advances for patients. In the last year, we delivered on our strategy to create accelerating value for all our stakeholders. With two independent commercial launches now underway, we transitioned into a fully integrated commercial-stage biotechnology company.

Headquarters
Carlsbad, CA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 9, 2026
Incorporated in
CA

Employees, at the top of the page: "As of February 19, 2026, we employed 1,402 people, the vast majority of whom reside in the U" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 26, 2026 (open at SEC), compared with the 10-K filed Feb 19, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/IONS/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.